A University of Nottingham spinout that uses its own gene-editing method to engineer hard-to-modify bacterial strains, offering strain development, fermentation and analytics to pharma and industrial biotech clients.
Why they'll be hiring in 2027. Raised £2m from the Midlands Engine Investment Fund II in October 2025 with a stated plan to double its team of 10 within two years, then signed a licensing deal with AbbVie in March 2026.